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TREATMENT OF LEUKEMIA AND RELATED DISORDERS 
WITH 6-MERCAPTOPURINE 
By F. H. Bethel1 and D. S. Thompson 
University of Michigan, Ann Arbor, Mich. 
Since February 1953, 48 patients d i c t e d  with leukemia and allied disorders 
have received 6-mercaptopurine a t  the University of Michigan Hospital and 
a t  the Simpson Memorial Institute. Eight of the patients died within three 
weeks of the time of institution of therapy, most of them receiving the drug for 
less than one week. The remaining 40 serve as the clinical material for the 
analysis of our therapeutic results. It is recognized that for comparisons of 
antileukemia agents from the standpoint of survival, all cases should be in- 
cluded. However, such a comparison is not possible for our series because of 
previous or subsequent use of agents other than 6-mercaptopurine in many 
instances. I t  is our purpose to evalute the nature of the response obtained 
with 6-mercaptopurine in those patients who received the drug alone for a suf- 
ficient time to permit observation of its effect. 
Our practice is largely confined to adults, and in the series of 40 cases only 
five patients were under 1.5 years of age. I t  soon became evident that our 
better therapeutic responses were being obtained in younger adults, and that 
the most satisfactory dividing line appeared to be a t  35. This is an arbitrary 
separation, of course, but one cannot help being impressed with the inability 
of the middle-aged and elderly patient having acute leukemia to restore any 
degree of normal hemopoiesis, even though leukemic cell proliferation is sup- 
pressed. 
Factors which influence the responsiveness of a case of leukemia to specific 
medication, include, in addition to the age of the patient, the cell type, the 
proliferative activity, and the degree of dedifferentiation. Duration of the 
disease before institution of treatment bears a relation to the therapeutic re- 
sponse, but this variable cannot be controlled or readily defined, and it may be 
expected to affect more or less equally the several categories of acute leukemia. 
The most undif- 
ferentiated type is the stem cell or hemocytoblastic. Those showing some cellu- 
lar differentiation are the lymphocytic, granulocytic, and monocytic. Less 
rapidly proliferating forms of leukemia are classed as subacute. Most sub- 
acute leukemias are granulocytic, and this type only is represented in the pres- 
ent series. Chronic leukemias show variable rates of cell proliferation and, until 
they become advanced, exhibit a relatively high degree of cell differentiation. 
In  addition to these forms there are the disseminated lymphocytic sarcoma 
and reticulum cell sarcoma, both of which may be leukemic. Employing the 
criteria for good and partial remissions suggested for the conference on 6-mer- 
captopurine on which this monograph is based, our results may be summarized 
as follows: 
There were three cases of acute hemocytoblastic leukemia, all under 35 years 
of age. Two of these patients had good remissions, and one a partial remission. 
The rapidly proliferating leukemias are classed as acute. 
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Of three patients 
under 35, two had good remissions and one a partial remission. One patient 
over 35 had a partial remission. 
The series includes 10 cases of acute granulocytic Ieukemia. Of the seven 
patients under 35, two had good remissions, four had partial remissions, and 
in one there was no favorable response. Of the three patients 35 years of age 
or over, one had a partial remission and two had no responses. 
Two of 
these patients were under 35; the one had a partial remission and the other no 
remission. The two patients who were over 35 failed to respond to 6-mercapto- 
purine. 
Of the two patients 
under 35, the one had a partial remission and the other no remission. Four 
patients 35 or over included three who had partial remissions and one who had 
no remission. 
S ix  patients having chronic granulocytic leukemia, all in the terminal acute 
stage of the disease, were treated with 6-mercaptopurine. Two were under 35, 
and four were 35 or older. All six patients had remissions which, from a hema- 
tologic standpoint, must be classed as partial, but clinically these remissions 
were good to excellent, and they lasted from a few weeks to several months. 
The series includes six cases of disseminated lymphocytic sarcoma, three 
under and three over 35 years. Two of the younger group had good remissions 
and one a partial remission. Of those over 35, two had partial remissions and 
one no remission. 
One patient over 35 years of age afflicted with wide-spread reticulum cell 
sarcoma obtained a partial remission while receiving 6-mercaptopurine. 
Discussion. The number of patients in each category is small, so that inter- 
pretation of the data must be regarded as tentative. The results so far obtained 
with 6-mercaptopurine indicate that favorable responses may be obtained in a 
high percentage of children and of young adults having acute leukemia. The 
most favorable effects, in our experience, have been observed in patients suffer- 
ing from acute hemocytoblastic and acute lymphocytic leukemia. Least ben- 
eficial results were obtained in monocytic leukemia. In all of our cases of acute 
leukemia under the age of 35, the percentage incidence of good remissions was 
28.6, whereas the incidence of partial remissions was 33.3 per cent. Over the 
age of 35 there were no good remissions, and only 2 partial remissions occurred 
among the six patients treated. 
In the less actively proliferative subacute leukemia of granulocytic type, no 
good remissions were obtained. Although patients having this form of the 
disease may be partially controlled and may have protracted illnesses, substan- 
tial hematologic and clinical improvement has not been observed in any of our 
cases. 
6-Mercaptopurine is an exceedingly useful drug, in our experience, in the 
management of the late stage of chronic granulocytic leukemia when other 
forms of therapy are no longer effective. A sense of well-being is usually tem- 
porarily restored to such patients, and the extreme hypermetabolism and 
apprehensiveness of the terminal phase of this disease is largely averted. 
There were four cases of acute lymphocytic leukemia. 
A total of four cases of acute monocytic leukemia were treated. 
There were six cases of subacute granulocytic leukemia. 
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The compound may be of considerable value in the treatment of dissemi- 
nated lymphosarcoma and reticulum cell sarcoma. 
No specific toxic effects, other than those on bone marrow, have been noted 
in association with 6-mercaptopurine therapy. Megaloblastoid transformation 
of erythropoiesis, such as may occur as a result of administration of folic acid 
antagonists, has rarely been observed after 6-mercaptopurine therapy. How- 
ever, prolonged administration, for a t  least four or five weeks, is accompanied 
by a peculiar change in the morphology and staining reaction of the nucleated 
erythroid elements in the marrow. The early normoblasts show a loss of 
normal nuclear chromatin architecture which can best be described as karyo- 
lysis. The chromatin strands swell, lose their normal distinct ropelike pattern 
and become hemogeneous opaque masses. Simultaneously there may be a 
great increase in the total number of nucleated erythrocytes. 
Conclusions. Forty-eight patients afflicted with leukemia were treated with 
6-mercaptopurine. The series included acute, subacute, and advanced chronic 
leukemia and disseminated malignant lymphoma. Evaluation of therapy is 
based on data obtained on 40 patients who were observed for a t  least three 
weeks. 
Dosage of 6-mercaptopurine was within the range of 2.0 to 3.0 mgm. per kilo 
of body weight daily for initial therapy, and a total of 25 to 50 mgm. daily for 
maintenance in adult cases. 
The results indicate that 6-mercaptopurine has a limited value in the treat- 
ment of acute leukemia, other than monocytic, in children and young adults. 
It is useful as palliation in the terminal stage of chronic granulocytic leukemia, 
and its administration may be temporarily beneficial in disseminated malignant 
lymphoma. 
The combined or sequential use of 6-mercaptopurine with other antimetabo- 
lites and with cortisone and ACTH has, in general, improved the outlook of 
patients having acute leukemia. 
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